Although the efficacy of combining HT and CDK4 and CDK6 inhibitor in patients with ESR1+/HER2− breast cancer, the promising benefit of CDK4 and CDK6 drug inhibitors in other neoplasms has not been extensively tested. The gene discussed is CDK4; the disease is breast cancer.